March 2024 in “PLoS medicine” Physical activity, height, and smoking affect prostate cancer risk.
November 2025 in “Preprints.org” New-onset fibromyalgia after COVID-19 is poorly understood and needs more research.
July 2025 in “PNAS Nexus” A new tool accurately identifies human cornea cell states and key factors.
1 citations
,
October 2019 in “Medicina UPB” Multiple treatment comparison meta-analyses help doctors make better decisions by comparing different interventions.
4 citations
,
May 2017 in “Data in Brief” Five molecular elements identified as potential future targets for hair loss therapy.
4 citations
,
September 2019 in “Journal of The American Academy of Dermatology” Platelet-rich plasma combined with other treatments improves acne scars better than those treatments alone.
February 2026 in “Postgraduate Medicine” This meta-analysis examined the risk of depression associated with 5-alpha reductase inhibitors (5-ARIs) across 5 longitudinal studies involving 2,517,859 patients. The findings indicate a 31% increased risk of depression with 5-ARI use, though this risk varies significantly depending on the control group used. Studies with non-drug controls reported a higher risk, while those with alpha-blocker comparators showed a decreased risk. The choice of comparator group was a major source of heterogeneity in the results. Overall, the risk of depression with 5-ARI use is likely minimal, with observational data suggesting a slight reduction in risk and randomized data indicating a potential slight increase. Previous reports of a much higher risk may have resulted from inappropriate control group selection.
April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
June 2017 in “Journal of The European Academy of Dermatology and Venereology” Alopecia patients have higher heart disease risk; statins and finasteride may help.
April 2015 in “Reactions Weekly” Finasteride toxicity information is limited, poor quality, and biased.
152 citations
,
October 2010 in “Archives of Dermatology” Finasteride helps hair growth but may cause sexual side effects.
40 citations
,
January 2013 in “Frontiers in Endocrinology” Finger length ratios are not linked to the number of specific gene repeats affecting testosterone sensitivity.
19 citations
,
October 2018 in “Medicine” Oriental herbal medicine with moxibustion may improve pregnancy rates and other symptoms in PCOS, but more high-quality research is needed.
15 citations
,
July 2021 in “JAMA Dermatology” Androgenetic alopecia negatively affects quality of life and self-esteem, especially in women, but not depression.
13 citations
,
February 2022 in “JAMA Dermatology” Spironolactone does not increase cancer risk and may lower prostate cancer risk, but more research is needed.
13 citations
,
February 2022 in “JAMA Dermatology” Dutasteride is the most effective hair loss treatment after 24 weeks, but finasteride leads to the most hair growth after 48 weeks.
12 citations
,
June 2023 in “JAMA network open” JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
2 citations
,
July 2023 in “Obstetrics & Gynecology” Imiquimod may be a better non-surgical treatment for cervical pre-cancer, but its effectiveness for vaginal pre-cancer is unclear, and it has some side effects.
March 2026 in “Nature Communications” Genetic factors, skin barrier, immune function, and obesity influence risk of fungal skin infections.
April 2023 in “Journal of Investigative Dermatology” People with Alopecia Areata are more likely to have certain health issues like ulcerative colitis and type 1 diabetes, but less likely to have others like hypertension and type 2 diabetes.
Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.
Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.
Dutasteride is more effective than finasteride for treating BPH without extra safety risks.
March 2013 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Prostate cancer screening doesn't significantly reduce death rates and has risks like overdiagnosis and side effects.
January 2023 in “The Annals of african surgery” Hormone treatment before hypospadias surgery can increase penis size and reduce surgery complications.
44 citations
,
September 2015 in “Annals of Oncology” Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
2 citations
,
January 2010 Finasteride helps improve hair growth in men with hair loss but may increase the risk of erectile dysfunction.
August 2025 in “Systematic Reviews” Photobiomodulation may improve certain health conditions, but more high-quality research is needed.
Platelet-rich plasma may improve hair transplant results.
January 2020 in “Publications of the UdS (Saarland University)” People with Alopecia areata often have lower Vitamin D levels.